Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Equillium, Inc. (EQ)

Equillium receives Australian clearance for EQ504 Phase 1 trial, dosing expected early November

Neutral Impact 3 of 5 product/contract Written later

Equillium said it received ethics committee approval and clearance from Australia's Therapeutic Goods Administration under the Clinical Trial Notification scheme for a Phase 1 trial of EQ504. The company expects to begin dosing healthy participants by early November 2026, moving the drug candidate closer to clinical data.

Key points

  • Approvals: Human Research Ethics Committee approval and TGA clearance in Australia for the EQ504 Phase 1 trial
  • Timing: Company expects to begin dosing healthy participants by early November 2026
  • Design: Randomized, double-blinded, placebo-controlled, single-center study with three parts, including a 10-day multiple ascending dose portion and a food effect cohort

The filing

CompanyEquillium, Inc. (EQ)
Form8-K, current report
Filed with the SECOct 5, 2026, 5:06 PM ET
Accession number0001193125-26-414364

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.